(Q28371530)

English

PDGFRA FIP1L1::PDGFRA

genetic variant

FIP1L1-PDGFRA
FIP1L1::PDGFRA

In more languages

Statements

transcript fusion

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/574

human chromosome 4

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/574

54243812

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/574

55141008

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/574

54294350

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/574

55164414

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/574

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/574

positive therapeutic predictor for

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

acute myeloid leukemia

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7378

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

acute myeloid leukemia

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7378

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1441

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

determination method

CIViC evidence level A

CIViC 3-star trust rating

medical condition treated

myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1445

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1774

Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1777

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/574

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371530&oldid=2014799852"